The prognostic role of lipoprotein (a) in the development of non-alcoholic fatty liver disease in young adults
https://doi.org/10.34680/2076-8052.2025.2(140).341-354
Abstract
In the study we assessed the levels of lipoprotein (a) in relation to clinical, laboratory, and instrumental parameters in young individuals with and without non-alcoholic fatty liver disease. This observational case-control study included 100 participants divided into two groups: Group 1 (“cases”) – 50 young individuals with non-alcoholic fatty liver disease; and Group 2 (“controls”) – 50 young individuals without non-alcoholic fatty liver disease. It was found that young individuals with non-alcoholic fatty liver disease had higher body mass index, waist circumference, waist-to-hip ratio, total fat mass, visceral fat, and serum triglyceride levels, as well as lower high-density lipoprotein cholesterol levels, compared to the control group. In addition, significantly higher serum concentrations of lipoprotein (a) were observed in the non-alcoholic fatty liver disease group. Multivariate analysis showed that lipoprotein (a) levels, along with age, male sex, and visceral fat levels, were independently associated with the development of non-alcoholic fatty liver disease in young individuals. In clinical practice, measuring lipoprotein (a) levels in high-risk groups may enhance early screening and risk stratification for non-alcoholic fatty liver disease.
About the Authors
E. D. Pankova
South Ural State Medical University
Russian Federation
Russian Federation
Chelyabinsk
V. S. Chulkov
South Ural State Medical University
Russian Federation
Russian Federation
Chelyabinsk
N. A. Ektova
South Ural State Medical University
Russian Federation
Russian Federation
Chelyabinsk
E. E. Minina
South Ural State Medical University
Russian Federation
Russian Federation
Chelyabinsk
V. A. Sumerkina
South Ural State Medical University
Russian Federation
Russian Federation
Chelyabinsk
References
1. Ivashkin V. T., Maevskaya M. V., Zharkova M. S., Kotovskaya Yu. V., Tkacheva O. N., Troshina E. A., Shestakova M. V., Maev I. V., Breder V. V., Gheivandova N. I., Doshchitsin V. L., Dudinskaya E. N., Ershova E. V., Kodzoeva Kh. B., Komshilova K. A., Korochanskaya N. V., Mayorov A. Yu., Mishina E. E., Nadinskaya M. Yu., Nikitin I. G., Pogosova N. V., Tarzimanova A. I., Shamkhalova M. Sh. Clinical practice guidelines of the Russian scientific liver society, Russian gastroenterological association, Russian association of endocrinologists, Russian association of gerontologists and geriatricians and National society for preventive cardiology on diagnosis and treatment of non-alcoholic liver disease // Russian journal of gastroenterology, hepatology, coloproctology. 2022. 32 (4). 104–140. DOI: 10.22416/1382-4376-2022-32-4-104-140 (In Russian).
2. Younossi Z. M., Golabi P., Paik J. M., Henry A., Van Dongen C., Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review // Hepatology. 2023. 77 (4). 1335–1347. DOI: 10.1097/HEP.0000000000000004
3. Polyzos S. A., Kechagias S., Tsochatzis E. A. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations // Alimentary pharmacology and therapentics. 2021. 54 (8). 1013–1025. DOI: 10.1111/apt.16575
4. Friedman S., Neuschwander-Tetri B., Rinella M., Sanyal A. Mechanisms of NAFLD development and therapeutic strategies // Nature medicine. 2018. 24 (7). 908–922. DOI: 10.1038/s41591-018-0104-9
5. Bhatia H., Becker R., Leibundgut G., Patel M., Lacaze P., Tonkin A., Narula J., Tsimikas S. Lipoprotein(a), platelet function and cardiovascular disease // Nature reviews cardiology. 2024. 21 (5). 299–311. DOI: 10.1038/s41569-023-00947-2
6. Wang Z., Yan X., Fang L., Tang J., Zhang J. Association between lipoprotein (a), fibrinogen and their combination with all-cause, cardiovascular disease and cancer-related mortality: findings from the NHANES // BMC public health. 2024. 24 (1). 1927. DOI: 10.1186/s12889-024-19443-4
7. Wang Z., Li M., Li J., Liu N. Association of lipoprotein (a) with all-cause and cause-specific mortality: A prospective cohort study // European journal of internal medicine. 2022. 106. 63–70. DOI: 10.1016/j.ejim.2022.09.010
8. Tsimikas S. A test in context: lipoprotein (a): diagnosis, prognosis, controversies, and emerging therapies // Journal of the American college of cardiology. 2017. 69 (6). 692–711. DOI: 10.1016/j.jacc.2016.11.042
9. Schmidt K., Noureen A., Kronenberg F., Utermann G. Structure, function, and genetics of lipoprotein (a) // Journal of lipid research. 2016. 57 (8). 1339–1359. DOI: 10.1194/jlr.R067314
10. Fan C., Ling-Hu A., Sun D., Gao W., Zhang C., Duan X., Li H., Tian W., Yu Q., Ke Z. Nobiletin ameliorates hepatic lipid deposition, oxidative stress, and inflammation by mechanisms that involve the Nrf2/NF-κB axis in nonalcoholic fatty liver disease // Journal of agricultural and food chemistry. 2023. 71 (50). 20105–20117. DOI: 10.1021/acs.jafc.3c06498
11. Pawlak M., Lefebvre P., Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease // Journal of hepatology. 2015. 62 (3). 720–733. DOI: 10.1016/j.jhep.2014.10.039
12. Pankova E. D., Chulkov V. S., Chulkov V. S., Minina E. E., Ektova N. A., Dmitrieva A. Yu., Gasanov M. Z. Cardiometabolic risk factors, metabolic profile and body composition in young adults with non-alcoholic fatty liver disease // Cardiovascular therapy and prevention. 2025. 24 (4). 33–39. DOI: 10.15829/1728-8800-2025-4094 (In Russian).
13. Chulkov V., Pankova E., Gavrilova E., Chulkov V., Minina E., Gasanov M. Lipoprotein a as a predictor of NAFLD in young adults // Atherosclerosis. 2024. 395. 117788. DOI: 10.1016/j.atherosclerosis.2024.117788
14. Kronenberg F., Mora S., Stroes E., Ference B., Arsenault B., Berglund L., Dweck M., Koschinsky M., Lambert G., Mach F., McNeal C., Moriarty P., Natarajan P., Nordestgaard B., Parhofer K., Virani S., von Eckardstein A., Watts G., Stock J., Ray K., Tokgözoğlu L., Catapano A. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement // European heart journal. 2022. 43 (39). 3925–3946. DOI: 10.1093/eurheartj/ehac361
15. Zewinger S., Kleber M., Tragante V., McCubrey R., Schmidt A., Direk K., Laufs U., Werner C., Koenig W., Rothenbacher D., Mons U., Breitling L., Brenner H., Jennings R., Petrakis I., Triem S., Klug M., Filips A., Blankenberg S., Waldeyer C., Sinning C., Schnabel R., Lackner K., Vlachopoulou E., Nygård O., Svingen G., Pedersen E., Tell G., Sinisalo J., Nieminen M., Laaksonen R., Trompet S., Smit R., Sattar N., Jukema J., Groesdonk H., Delgado G., Stojakovic T., Pilbrow A., Cameron V., Richards A., Doughty R., Gong Y., Cooper-DeHoff R., Johnson J., Scholz M., Beutner F., Thiery J., Smith J., Vilmundarson R., McPherson R., Stewart A., Cresci S., Lenzini P., Spertus J., Olivieri O., Girelli D., Martinelli N., Leiherer A., Saely C., Drexel H., Mündlein A., Braund P., Nelson C., Samani N., Kofink D., Hoefer I., Pasterkamp G., Quyyumi A., Ko Y., Hartiala J., Allayee H., Tang W., Hazen S., Eriksson N., Held C., Hagström E., Wallentin L., Akerblom A., Siegbahn A., Karp I., Labos C., Pilote L., Engert J., Brophy J., Thanassoulis G., Bogaty P., Szczeklik W., Kaczor M., Sanak M., Virani S., Ballantyne C., Lee V., Boerwinkle E., Holmes M., Horne B., Hingorani A., Asselbergs F., Patel R.; GENIUS-CHD consortium; Krämer B., Scharnagl H., Fliser D., März W., Speer T. Relations between lipoprotein (a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study // Lancet diabetes and endocrinology. 2017. 5 (7). 534–543. DOI: 10.1016/S2213-8587(17)30096-7
16. Langsted A., Nordestgaard B., Kamstrup P. Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study // European heart journal. 2021. 42 (12). 1147–1156. DOI: 10.1093/eurheartj/ehaa1085
17. Gudbjartsson D., Thorgeirsson G., Sulem P., Helgadottir A., Gylfason A., Saemundsdottir J., Bjornsson E., Norddahl G., Jonasdottir A., Jonasdottir A., Eggertsson H., Gretarsdottir S., Thorleifsson G., Indridason O., Palsson R., Jonasson F., Jonsdottir I., Eyjolfsson G., Sigurdardottir O., Olafsson I., Danielsen R., Matthiasson S., Kristmundsdottir S., Halldorsson B., Hreidarsson A., Valdimarsson E., Gudnason T., Benediktsson R., Steinthorsdottir V., Thorsteinsdottir U., Holm H., Stefansson K. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes // Journal of the American college of cardiology. 2019. 74 (24). 2982–2994. DOI: 10.1016/j.jacc.2019.10.019
18. Krolevets T. S., Syrovenko M. I., Livzan M. A. Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity // Russian journal of evidence-based gastroenterology. 2023. 12 (4). 43–53. DOI: 10.17116/dokgastro20231204143 (In Russian).
19. Meroni M., Longo M., Lombardi R., Paolini E., Macchi C., Corsini A., Sirtori C., Fracanzani A., Ruscica M., Dongiovanni P. Low lipoprotein (a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease // Hepatology communications. 2022. 6 (3). 535–549. DOI: 10.1002/hep4.1830
20. Li C., Li M., Wang Z. There is a linear negative correlation between lipoprotein(a) and non-alcoholic fatty liver disease // Scientific reports. 2025. 15. 8538. DOI: 10.1038/s41598-025-93518-z
21. Mehta A., Lee T., Alebna P., Grandhi G., Dixon D., Salloum F., Sanyal A., Siddiqui M. Discordant association of nonalcoholic fatty liver disease with lipoprotein (a) and markers of atherogenic dyslipidemia // Journal of clinical lipidology. 2023. 17 (6). 828–833. DOI: 10.1016/j.jacl.2023.09.003
22. Chulkov V. S., Lenets E. A., Chulkov V. S., Gavrilova E. S., Minina E. E., Zhdanova O. V. Gender characteristics of the pathogenesis, prevention and treatment of metabolic syndrome // Arterial hypertension. 2020. 26 (4). 371–382. DOI: 10.18705/1607-419X-2020-26-4-371-382 (In Russian).
Review
For citations:
Pankova E.D., Chulkov V.S., Ektova N.A., Minina E.E., Sumerkina V.A. The prognostic role of lipoprotein (a) in the development of non-alcoholic fatty liver disease in young adults. Title in english. 2025;(2(140)):341-354. (In Russ.) https://doi.org/10.34680/2076-8052.2025.2(140).341-354
Views:
14
Email this article 